Cleared Traditional

VIVONEX MASS GASTRASTOMY TUBE (K822516) - FDA 510(k) Clearance

Class I Immunology device.

K822516 · Norwich Eaton Pharmaceuticals, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1982
Decision
18d
Days
Class 1
Risk

K822516 is an FDA 510(k) clearance for the VIVONEX MASS GASTRASTOMY TUBE. Classified as Fraction V, Antigen, Antiserum, Control (product code KHT), Class I - General Controls.

Submitted by Norwich Eaton Pharmaceuticals, Inc. (Mchenry, US). The FDA issued a Cleared decision on September 7, 1982 after a review of 18 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5370 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Norwich Eaton Pharmaceuticals, Inc. devices

Submission Details

510(k) Number K822516 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 20, 1982
Decision Date September 07, 1982
Days to Decision 18 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
86d faster than avg
Panel avg: 104d · This submission: 18d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code KHT Fraction V, Antigen, Antiserum, Control
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.5370
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.